DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $584,663,034 | +121.8% | 2,356,562 | +114.6% | 1.18% | +129.9% |
| Q2 2023 | $263,541,600 | -25.9% | 1,098,090 | -22.2% | 0.52% | -31.9% |
| Q1 2023 | $355,611,298 | +63.0% | 1,410,932 | +71.7% | 0.76% | +54.0% |
| Q4 2022 | $218,121,890 | +880.6% | 821,799 | +854.3% | 0.49% | +902.0% |
| Q3 2022 | $22,244,000 | +8.9% | 86,115 | +23.7% | 0.05% | +25.6% |
| Q1 2022 | $20,424,000 | -81.3% | 69,629 | -79.1% | 0.04% | -80.7% |
| Q4 2021 | $109,512,000 | +161.7% | 332,852 | +142.1% | 0.20% | +16.1% |
| Q3 2021 | $41,852,000 | -68.2% | 137,471 | -72.0% | 0.17% | -70.8% |
| Q2 2021 | $131,725,000 | +328.3% | 490,849 | +259.2% | 0.60% | +322.7% |
| Q1 2021 | $30,758,000 | -64.3% | 136,649 | -64.8% | 0.14% | -69.8% |
| Q4 2020 | $86,249,000 | +277.4% | 388,258 | +265.8% | 0.47% | +219.9% |
| Q3 2020 | $22,855,000 | -59.3% | 106,138 | -66.6% | 0.15% | -62.8% |
| Q2 2020 | $56,165,000 | +5762.7% | 317,620 | +4986.8% | 0.39% | +5514.3% |
| Q4 2019 | $958,000 | -98.8% | 6,244 | -98.9% | 0.01% | -98.9% |
| Q3 2019 | $79,964,000 | +1825.9% | 553,657 | +1805.5% | 0.63% | +1750.0% |
| Q2 2019 | $4,152,000 | -86.9% | 29,055 | -87.9% | 0.03% | -77.3% |
| Q1 2019 | $31,730,000 | +5351.9% | 240,350 | +4160.0% | 0.15% | +2400.0% |
| Q4 2018 | $582,000 | -95.6% | 5,642 | -95.3% | 0.01% | -89.3% |
| Q3 2018 | $13,136,000 | +1290.1% | 120,900 | +1162.5% | 0.06% | +300.0% |
| Q2 2018 | $945,000 | -41.5% | 9,576 | -45.0% | 0.01% | -79.4% |
| Q4 2017 | $1,616,000 | +30.1% | 17,412 | +17.7% | 0.07% | +23.6% |
| Q2 2017 | $1,242,000 | -27.0% | 14,788 | -25.2% | 0.06% | -32.9% |
| Q1 2017 | $1,701,000 | -98.4% | 19,777 | -98.6% | 0.08% | -88.5% |
| Q4 2016 | $107,923,000 | +121.2% | 1,386,477 | +122.8% | 0.71% | +104.6% |
| Q3 2016 | $48,789,000 | +838.2% | 622,392 | +1108.8% | 0.35% | +688.6% |
| Q2 2016 | $5,200,000 | -6.6% | 51,488 | -12.3% | 0.04% | -18.5% |
| Q1 2016 | $5,569,000 | +576.7% | 58,707 | +562.4% | 0.05% | +575.0% |
| Q4 2015 | $823,000 | -53.1% | 8,863 | -56.9% | 0.01% | -63.6% |
| Q3 2015 | $1,754,000 | -23.8% | 20,583 | -23.4% | 0.02% | -26.7% |
| Q2 2015 | $2,301,000 | -93.5% | 26,881 | -93.5% | 0.03% | -93.5% |
| Q1 2015 | $35,279,000 | +313.5% | 415,536 | +317.4% | 0.46% | +307.1% |
| Q4 2014 | $8,532,000 | -49.3% | 99,553 | -53.4% | 0.11% | -54.4% |
| Q2 2014 | $16,814,000 | – | 213,562 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |